Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, announced a multi-year research collaboration agreement. This partnership will explore innovative approaches to modulate the immune system and regulate inflammatory responses, which play key roles in the progression of a wide range of cardiovascular diseases.

This collaboration combines Bitterroot Bio's expertise in cardiovascular medicine and biology with Biotheus' advanced capabilities in designing novel protein therapeutics. Together, the companies will focus on discovering and developing medicines that may offer new hope for patients suffering from atherosclerosis and other life-threatening cardiovascular conditions.

Pavan Cheruvu, MD, CEO of Bitterroot Bio, stated, "We are thrilled to partner with Biotheus to leverage their cutting-edge antibody design technology. This collaboration represents a significant step forward in our quest to develop innovative treatments that can fundamentally change the way cardiovascular diseases are treated."

Xiaolin Liu, PhD, CEO of Biotheus, added, "Joining forces with Bitterroot Bio is an exciting opportunity for Biotheus to apply our expertise in bispecific and multi-specific antibody development towards addressing critical needs in cardiovascular medicine. We are confident that this collaboration will lead to breakthroughs that benefit patients worldwide."

Under the terms of the agreement, the companies will engage in joint research and development with a goal of nominating product candidates for further development in preclinical and clinical studies.